Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserman, Matt, Palacios, Maria Gabriela, Grajales, Ana Gabriela, Wilson, Michele, McDade, Cheryl, Farkouh, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Reply Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988870/
https://www.ncbi.nlm.nih.gov/pubmed/30657407
http://dx.doi.org/10.1080/21645515.2018.1558691
_version_ 1783492325204295680
author Wasserman, Matt
Palacios, Maria Gabriela
Grajales, Ana Gabriela
Wilson, Michele
McDade, Cheryl
Farkouh, Raymond
author_facet Wasserman, Matt
Palacios, Maria Gabriela
Grajales, Ana Gabriela
Wilson, Michele
McDade, Cheryl
Farkouh, Raymond
author_sort Wasserman, Matt
collection PubMed
description In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.
format Online
Article
Text
id pubmed-6988870
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69888702020-02-14 Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’” Wasserman, Matt Palacios, Maria Gabriela Grajales, Ana Gabriela Wilson, Michele McDade, Cheryl Farkouh, Raymond Hum Vaccin Immunother Reply Letter In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations. Taylor & Francis 2019-01-18 /pmc/articles/PMC6988870/ /pubmed/30657407 http://dx.doi.org/10.1080/21645515.2018.1558691 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Reply Letter
Wasserman, Matt
Palacios, Maria Gabriela
Grajales, Ana Gabriela
Wilson, Michele
McDade, Cheryl
Farkouh, Raymond
Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title_full Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title_fullStr Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title_full_unstemmed Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title_short Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
title_sort comment on gomez et. al. “response to article by wasserman et. al. (2018) ‘modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in mexico’”
topic Reply Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988870/
https://www.ncbi.nlm.nih.gov/pubmed/30657407
http://dx.doi.org/10.1080/21645515.2018.1558691
work_keys_str_mv AT wassermanmatt commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT palaciosmariagabriela commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT grajalesanagabriela commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT wilsonmichele commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT mcdadecheryl commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT farkouhraymond commentongomezetalresponsetoarticlebywassermanetal2018modellingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico

Ejemplares similares